Loading...
Docoh

Anebulo Pharmaceuticals (ANEB)

Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.

ANEB stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 May 22
11 Aug 22
30 Jun 23
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jun 22 Cundy Kenneth C Option to purchase Common Stock Common Stock Grant Acquire A No No 2.91 350,169 1.02M 350,169
7 Feb 22 Simon Allen Option to purchase Common Stock Common Stock Grant Acquire A No No 6.15 625,000 3.84M 625,000
17 Dec 21 Aron R. English Common Stock, par value $0.001 per share Buy Acquire P Yes No 6.5858 400 2.63K 3,362,713
37.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 10 3 +233.3%
Opened positions 8 1 +700.0%
Closed positions 1 8 -87.5%
Increased positions 0 1 EXIT
Reduced positions 1 0 NEW
13F shares Current Prev Q Change
Total value 29.54M 52K +56705.8%
Total shares 8.84M 4.66M +89.7%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Aron R. English 4.65M $0 0.0%
22NW 3.36M $23.81M NEW
Mangrove Partners 399.22K $2.83M NEW
Laurion Capital Management 219.58K $1.48M NEW
Ikarian Capital 181.2K $1.23M NEW
Boothbay Fund Management 17.33K $123K NEW
BLK Blackrock 7.45K $53K -4.6%
UBS UBS Group AG - Registered Shares 2.16K $15K NEW
Tower Research Capital 756 $5K NEW
MS Morgan Stanley 3 $0 NEW
Largest transactions Shares Bought/sold Change
22NW 3.36M +3.36M NEW
Mangrove Partners 399.22K +399.22K NEW
Laurion Capital Management 219.58K +219.58K NEW
Ikarian Capital 181.2K +181.2K NEW
Boothbay Fund Management 17.33K +17.33K NEW
UBS UBS Group AG - Registered Shares 2.16K +2.16K NEW
Tower Research Capital 756 +756 NEW
Advisor 0 -500 EXIT
BLK Blackrock 7.45K -360 -4.6%
MS Morgan Stanley 3 +3 NEW

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Jumpstart, repayment, smaller
Removed: applicability, assessed, ASU, beginning, closed, conformity, currency, declared, demand, director, existing, exposed, exposure, FASB, indirectly, minimal, previously, quarter, registration, removing, repaid, Simplifying, subsequent, tax, Topic